Drugs / NXC-201
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04720313 | Jan 2021 → Jan 2026 overdue | — | Hadassah Medical Organization | Active not recruiting | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT06097832 | Jun 2024 → Dec 2026 expected | AL amyloidosis | Nexcella Inc. | Active not recruiting | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT07709715 | Jan 2027 → Dec 2028 expected | AL amyloidosis | Nexcella Inc. | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NXC-201 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04720313 ↗ |
| Known as | HBI0101 | “NXC-201 (formerly HBI0101) CART is defined as autologous T cells transduced ex-vivo with anti-BCMA CAR retroviral vector encoding the chimeric antigen receptor (CAR) targeted...” NCT04720313 ↗ |
| Modality | Cell therapy | “autologous T cells transduced ex-vivo with anti-BCMA CAR retroviral vector encoding the chimeric antigen receptor (CAR) targeted to human BCMA.” NCT06097832 ↗ |